NASDAQ:ARDS Aridis Pharmaceuticals (ARDS) Stock Forecast, Price & News $0.29 +0.01 (+3.57%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.24▼$0.3050-Day Range$0.16▼$0.4052-Week Range$0.15▼$2.77Volume2.74 million shsAverage Volume2.90 million shsMarket Capitalization$10.46 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aridis Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,970.4% Upside$6.00 Price TargetShort InterestHealthy2.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 stars 3.3 Analyst's Opinion Consensus RatingAridis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Aridis Pharmaceuticals has a forecasted upside of 1,970.4% from its current price of $0.29.Amount of Analyst CoverageAridis Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.10% of the outstanding shares of Aridis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAridis Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aridis Pharmaceuticals has recently increased by 86.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAridis Pharmaceuticals does not currently pay a dividend.Dividend GrowthAridis Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARDS. Previous Next 3.9 News and Social Media Coverage News SentimentAridis Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aridis Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for ARDS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added Aridis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aridis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.90% of the stock of Aridis Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.89% of the stock of Aridis Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aridis Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aridis Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Aridis Pharmaceuticals (NASDAQ:ARDS) StockAridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.Read More Receive ARDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDS Stock News HeadlinesJune 1, 2023 | benzinga.comAridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and ForecastMay 31, 2023 | finance.yahoo.comAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignJune 2, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 25, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QMay 12, 2023 | americanbankingnews.comAridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Sees Significant Decrease in Short InterestApril 26, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KApril 23, 2023 | americanbankingnews.comCritical Analysis: Aridis Pharmaceuticals (NASDAQ:ARDS) and Veru (NASDAQ:VERU)April 3, 2023 | bizjournals.comBig pharma, small drug maker spar over pneumonia drug dealJune 2, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.March 31, 2023 | finance.yahoo.comAridis Provides Corporate UpdateMarch 29, 2023 | msn.comAstraZeneca Axes Pneumonia Drug Pact With AridisMarch 28, 2023 | americanbankingnews.comAridis Pharmaceuticals (ARDS) Set to Announce Quarterly Earnings on WednesdayMarch 28, 2023 | americanbankingnews.comAridis Pharmaceuticals (ARDS) to Release Quarterly Earnings on WednesdayMarch 14, 2023 | msn.comWhy Aridis Pharmaceuticals Shares Are DivingMarch 14, 2023 | marketwatch.comAridis Pharmaceuticals Shares Tumble After Stock Offering >ARDSMarch 14, 2023 | msn.comAridis (ARDS) Stock Up as Cystic Fibrosis Study Meets GoalsMarch 14, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common StockMarch 13, 2023 | msn.comAridis Skyrockets on Impressive Data In Cystic FibrosisMarch 13, 2023 | msn.comAridis stock surges ~35% as lung disease drug AR-501 meets main goal in mid-stage studyMarch 13, 2023 | finance.yahoo.comWhy Aridis Pharmaceuticals Shares Are Soaring TodayMarch 13, 2023 | marketwatch.comAridis Shares Rally Premarket on Positive Phase 2a Cystic Fibrosis Study >ARDSMarch 13, 2023 | finance.yahoo.comAridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis PatientsFebruary 17, 2023 | finanznachrichten.deInterviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money ReportFebruary 15, 2023 | finance.yahoo.comWhen Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?February 6, 2023 | finance.yahoo.comIn virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay AreaFebruary 1, 2023 | finance.yahoo.comHere's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock NowJanuary 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)See More Headlines ARDS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDS Company Calendar Last Earnings11/10/2021Today6/02/2023Next Earnings (Estimated)6/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDS CUSIPN/A CIK1614067 Webwww.aridispharma.com Phone(408) 385-1742Fax408-960-3822Employees33Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+1,982.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,370,000.00 Net Margins-982.56% Pretax Margin-982.56% Return on EquityN/A Return on Assets-175.57% Debt Debt-to-Equity RatioN/A Current Ratio0.32 Quick Ratio0.32 Sales & Book Value Annual Sales$3.09 million Price / Sales3.36 Cash FlowN/A Price / Cash FlowN/A Book Value($1.16) per share Price / Book-0.25Miscellaneous Outstanding Shares36,080,000Free Float31,424,000Market Cap$10.39 million OptionableNot Optionable Beta0.93 Key ExecutivesVu L. TruongDirector, Chief Executive & Scientific OfficerFred KurlandChief Financial & Accounting OfficerHasan JafriChief Medical OfficerSteven M. ChamowVice President-Research & DevelopmentLisa SherHead-Investor & Public RelationsKey CompetitorsObsEvaNASDAQ:OBSVAileron TherapeuticsNASDAQ:ALRNBenitec BiopharmaNASDAQ:BNTCAytu BioPharmaNASDAQ:AYTUTenax TherapeuticsNASDAQ:TENXView All CompetitorsInstitutional OwnershipSabby Management LLCBought 2,140,174 shares on 5/16/2023Ownership: 7.115%Commonwealth Equity Services LLCBought 71,000 shares on 5/11/2023Ownership: 2.148%Simplex Trading LLCSold 300 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions ARDS Stock - Frequently Asked Questions Should I buy or sell Aridis Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDS shares. View ARDS analyst ratings or view top-rated stocks. What is Aridis Pharmaceuticals' stock price forecast for 2023? 2 analysts have issued 1 year price objectives for Aridis Pharmaceuticals' stock. Their ARDS share price forecasts range from $2.00 to $10.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 1,982.6% from the stock's current price. View analysts price targets for ARDS or view top-rated stocks among Wall Street analysts. How have ARDS shares performed in 2023? Aridis Pharmaceuticals' stock was trading at $1.18 at the start of the year. Since then, ARDS stock has decreased by 75.6% and is now trading at $0.2881. View the best growth stocks for 2023 here. Are investors shorting Aridis Pharmaceuticals? Aridis Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 756,200 shares, an increase of 87.0% from the April 30th total of 404,400 shares. Based on an average trading volume of 881,700 shares, the short-interest ratio is presently 0.9 days. View Aridis Pharmaceuticals' Short Interest. When is Aridis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 5th 2023. View our ARDS earnings forecast. How were Aridis Pharmaceuticals' earnings last quarter? Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) issued its earnings results on Wednesday, November, 10th. The company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $1.43. The firm earned $0.52 million during the quarter. What other stocks do shareholders of Aridis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX). When did Aridis Pharmaceuticals IPO? (ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers. What is Aridis Pharmaceuticals' stock symbol? Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS." Who are Aridis Pharmaceuticals' major shareholders? Aridis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sabby Management LLC (7.12%), Commonwealth Equity Services LLC (2.15%) and Simplex Trading LLC (0.00%). Insiders that own company stock include John F Hamilton and Vu Truong. View institutional ownership trends. How do I buy shares of Aridis Pharmaceuticals? Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aridis Pharmaceuticals' stock price today? One share of ARDS stock can currently be purchased for approximately $0.29. How much money does Aridis Pharmaceuticals make? Aridis Pharmaceuticals (NASDAQ:ARDS) has a market capitalization of $10.39 million and generates $3.09 million in revenue each year. The company earns $-30,370,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. How can I contact Aridis Pharmaceuticals? Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The official website for the company is www.aridispharma.com. The company can be reached via phone at (408) 385-1742, via email at jwong@bplifescience.com, or via fax at 408-960-3822. This page (NASDAQ:ARDS) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.